Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

View website Save this grant

Next deadline: Jan 19, 2024

Later deadlines: Feb 21, 2024, Mar 21, 2024, Jun 20, 2024, Jul 19, 2024, Oct 21, 2024, Nov 21, 2024, Feb 21, 2025, Mar 21, 2025, Jun 23, 2025, Jul 23, 2025, Oct 20, 2025, Nov 20, 2025, Feb 20, 2026, Mar 20, 2026, Jun 22, 2026, Jul 22, 2026, Oct 19, 2026, Nov 19, 2026

Grant amount: Unspecified amount

Fields of work: Dementia & Alzheimer’s Disease

Applicant type: Nonprofit, Government Entity, Indigenous Group, For-Profit Business

Funding uses: Research

Location of project: Anywhere in the world

Location of residency: Anywhere in the world

Overview:

NOTE: There is currently one deadline for Letters of Intent; January 19, 2024. Applicants with questions about future deadlines are advised to contact a program officer.

The following full proposal deadlines apply to standard grant applications (due by 5:00 pm local time of applicant organization):

February 21, 2024
June 20, 2024
October 21, 2024
February 21, 2025
June 23 , 2025
October 20, 2025
February 20, 2026
June 22, 2026
October 19, 2026

The following full proposal deadlines apply to Renewal/Resubmission/Revision grant applications (due by 5:00 pm local time of applicant organization):

March 21, 2024
July 19, 2024
November 21, 2024
March 21, 2025
July 23 , 2025
November 20, 2025
March 20, 2026
July 22, 2026
November 19, 2026

The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

US Dept. of Health & Human Services: National Institutes of Health (NIH)
FUNDER

SAVED OPPORTUNITIES

No saved opportunities from this funder yet

FUNDER NOTES

Save this opportunity to add notes...

CONTACTS

Save this opportunity to add contacts...

Other Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

Forecasted Funding Opportunities from Us Dept. Of Health & Human Services: National Institutes Of Health (Nih)

Don’t miss out on other good fit funders!

See even more similar funders by creating a free 14-day account. Get personalized grant recommendations, tracking and more.

“Through Instrumentl, I was able to accomplish in 6 hours...SIX HOURS...what would have taken days or weeks with [another] search engine.”

Farrell Rouse Grants Manager KVC Health Systems

This page was last reviewed August 24, 2023 and last updated August 24, 2023